Latest Insider Transactions at Windtree Therapeutics Inc (WINT)
This section provides a real-time view of insider transactions for Windtree Therapeutics Inc (WINT). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of WINDTREE THERAPEUTICS INC to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of WINDTREE THERAPEUTICS INC 's insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Oct 08
2024
|
Craig Fraser President and CEO |
BUY
Open market or private purchase
|
Direct |
5,431
+38.6%
|
$0
$0.91 P/Share
|
|
Sep 27
2023
|
Craig Fraser President and CEO |
BUY
Open market or private purchase
|
Direct |
2,500
+4.14%
|
$2,500
$1.02 P/Share
|
|
Sep 26
2023
|
Craig Fraser President and CEO |
BUY
Open market or private purchase
|
Direct |
2,500
+4.32%
|
$0
$0.9 P/Share
|
|
Aug 23
2023
|
Daniel E. Geffken Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,033
+48.31%
|
-
|
|
Aug 23
2023
|
Eric Curtis SVP & COO |
BUY
Grant, award, or other acquisition
|
Direct |
14,667
+47.95%
|
-
|
|
Aug 23
2023
|
Steven Simonson SVP, Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
15,867
+47.64%
|
-
|
|
Aug 23
2023
|
Robert A Scott Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,033
+48.8%
|
-
|
|
Aug 23
2023
|
Mark Strobeck Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,300
+50.0%
|
-
|
|
Aug 23
2023
|
Leslie J. Williams Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,033
+48.8%
|
-
|
|
Aug 23
2023
|
Craig Fraser President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
45,867
+46.45%
|
-
|
|
Apr 26
2023
|
Craig Fraser President and CEO |
BUY
Open market or private purchase
|
Direct |
1,497
+17.6%
|
$1,497
$1.77 P/Share
|
|
Apr 25
2023
|
Craig Fraser President and CEO |
BUY
Open market or private purchase
|
Direct |
1,315
+19.26%
|
$1,315
$1.89 P/Share
|
|
Feb 28
2023
|
Diane Carman SVP & General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
99
-7.47%
|
-
|
|
Feb 28
2023
|
Eric Curtis SVP & COO |
SELL
Payment of exercise price or tax liability
|
Direct |
99
-7.32%
|
-
|
|
Feb 28
2023
|
Craig Fraser President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
334
-7.37%
|
-
|
|
Feb 28
2023
|
Steven Simonson SVP, Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
100
-5.98%
|
-
|
|
Feb 22
2023
|
James Huang Director |
BUY
Exercise of in-the-money or at-the-money derivatives securities
|
Indirect |
1,112,308
+24.38%
|
$0
$0.14 P/Share
|
|
Jul 27
2022
|
Craig Fraser President and CEO |
BUY
Open market or private purchase
|
Direct |
2,500
+1.09%
|
$0
$0.38 P/Share
|
|
Jul 26
2022
|
John P. Hamill SVP & CFO |
BUY
Open market or private purchase
|
Direct |
3,000
+3.96%
|
$0
$0.37 P/Share
|
|
Jul 26
2022
|
Craig Fraser President and CEO |
BUY
Open market or private purchase
|
Direct |
2,500
+1.1%
|
$0
$0.37 P/Share
|
|
Jun 30
2022
|
Craig Fraser President and CEO |
BUY
Open market or private purchase
|
Direct |
4,500
+1.99%
|
$0
$0.43 P/Share
|
|
Jun 29
2022
|
Craig Fraser President and CEO |
BUY
Open market or private purchase
|
Direct |
7,000
+3.12%
|
$0
$0.42 P/Share
|
|
Jun 07
2022
|
Daniel E. Geffken Director |
BUY
Grant, award, or other acquisition
|
Direct |
5,000
+41.43%
|
-
|
|
Jun 07
2022
|
James Huang Director |
BUY
Grant, award, or other acquisition
|
Direct |
5,000
+1.66%
|
-
|
|
Jun 07
2022
|
Robert A Scott Director |
BUY
Grant, award, or other acquisition
|
Direct |
5,000
+50.0%
|
-
|
|
Jun 07
2022
|
Leslie J. Williams Director |
BUY
Grant, award, or other acquisition
|
Direct |
5,000
+50.0%
|
-
|
|
Mar 16
2022
|
Craig Fraser President and CEO |
BUY
Open market or private purchase
|
Direct |
2,000
+0.94%
|
$0
$0.98 P/Share
|
|
Mar 15
2022
|
Craig Fraser President and CEO |
BUY
Open market or private purchase
|
Direct |
3,000
+1.42%
|
$0
$0.98 P/Share
|
|
Mar 15
2022
|
Steven Simonson SVP, Chief Medical Officer |
BUY
Open market or private purchase
|
Direct |
5,000
+5.64%
|
$5,000
$1.0 P/Share
|
|
Mar 04
2022
|
Diane Carman SVP & General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
66,300
+50.0%
|
-
|
|
Mar 04
2022
|
Eric Curtis SVP & COO |
BUY
Grant, award, or other acquisition
|
Direct |
66,300
+49.52%
|
-
|
|
Mar 04
2022
|
Craig Fraser President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
166,900
+44.87%
|
-
|
|
Mar 04
2022
|
John P. Hamill SVP & CFO |
BUY
Grant, award, or other acquisition
|
Direct |
66,300
+48.71%
|
-
|
|
Mar 04
2022
|
Steven Simonson SVP, Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
66,300
+45.76%
|
-
|
|
Dec 30
2021
|
Bioengine Capital Inc. > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
1,239,088
-100.0%
|
$1,239,088
$1.6 P/Share
|
|
Dec 30
2021
|
Center Laboratories, Inc. > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
1,239,088
+50.0%
|
$1,239,088
$1.6 P/Share
|
|
Nov 19
2021
|
Craig Fraser President and CEO |
BUY
Open market or private purchase
|
Direct |
930
+2.38%
|
$930
$1.6 P/Share
|
|
Nov 18
2021
|
Craig Fraser President and CEO |
BUY
Open market or private purchase
|
Direct |
930
+2.44%
|
$930
$1.61 P/Share
|
|
Oct 22
2021
|
Craig Fraser President and CEO |
BUY
Open market or private purchase
|
Direct |
3,000
+7.63%
|
$3,000
$1.9 P/Share
|
|
Oct 19
2021
|
Craig Fraser President and CEO |
BUY
Open market or private purchase
|
Direct |
3,000
+8.26%
|
$3,000
$1.91 P/Share
|
|
Oct 19
2021
|
James Huang Director |
BUY
Open market or private purchase
|
Direct |
50,000
+14.65%
|
$50,000
$1.9 P/Share
|
|
Apr 16
2021
|
Craig Fraser President and CEO |
BUY
Open market or private purchase
|
Direct |
1,000
+3.2%
|
$2,000
$2.09 P/Share
|
|
Apr 16
2021
|
John P. Hamill SVP & CFO |
BUY
Open market or private purchase
|
Direct |
1,000
+22.22%
|
$2,000
$2.07 P/Share
|
|
Apr 15
2021
|
Craig Fraser President and CEO |
BUY
Open market or private purchase
|
Direct |
1,000
+3.3%
|
$2,000
$2.24 P/Share
|
|
Apr 07
2021
|
Eric Curtis SVP & COO |
BUY
Open market or private purchase
|
Direct |
791
+37.99%
|
$1,582
$2.52 P/Share
|
|
Apr 06
2021
|
Craig Fraser President and CEO |
BUY
Open market or private purchase
|
Direct |
500
+1.74%
|
$1,000
$2.57 P/Share
|
|
Apr 05
2021
|
Craig Fraser President and CEO |
BUY
Open market or private purchase
|
Direct |
1,000
+3.47%
|
$2,000
$2.58 P/Share
|
|
Apr 01
2021
|
Craig Fraser President and CEO |
BUY
Open market or private purchase
|
Direct |
500
+1.83%
|
$1,000
$2.46 P/Share
|
|
Mar 31
2021
|
James Huang Director |
BUY
Open market or private purchase
|
Direct |
150,000
+46.73%
|
$300,000
$2.36 P/Share
|
|
Mar 31
2021
|
Craig Fraser President and CEO |
BUY
Open market or private purchase
|
Direct |
500
+1.87%
|
$1,000
$2.32 P/Share
|